Find A Lawyer
Near You

Contact us today for a complimentary consultation with a qualified attorney near you.

Bextra Injury

Bextra injury risks are so great that the FDA has ordered Pfizer, the makers of this prescription drug, to suspend all US Bextra sales. This Bextra recall took place officially in the United States on April 7, 2005. Bextra sales have also been suspended on European markets as a result of serious Bextra injury risks. The FDA ordered the Bextra recall after regulators concluded that the overall risk of Bextra injury is far greater than this drug's intended benefits.

Bextra is a COX-2 non-steroidal anti-inflammatory drug (NSAID) approved by the FDA in 2001 to treat patients with arthritis, menstrual cramps, and other chronic pain disorders. Bextra is in the same class of prescription drugs as Vioxx and Celebrex. Concern about Bextra injury risks mounted after Vioxx was recalled in September 2004. The Vioxx recall was prompted by studies which found increased cardiovascular risks associated with long term Vioxx use.

After the Vioxx recall, Pfizer consistently maintained that these risks were unique to Vioxx can did not indicate any possible cardiovascular Bextra injury risks. In November 2004, Pfizer was forced to swallow these words after Bextra clinical studies indicated similar cardiovascular Bextra injury risks. Patients recovering from heart surgery were two times more likely to suffer a heart attack, stoke, blood clot, or a similar event when taking Bextra compared to those not taking this pain medication.

Despite knowledge of increased cardiovascular Bextra injury risks, Pfizer made no indication that they intended to initiate a Bextra recall. These cardiovascular Bextra risks were not the only Bextra injury risks that Pfizer knew about. For years Pfizer has known that Bextra causes a serious and deadly Bextra injury called Stevens Johnson syndrome. This Bextra injury assails the skin and mucous membranes and essentially burns a person up from the inside out. This Bextra injury has claimed the lives of several Bextra users, yet Pfizer has still maintained that their product is safe.

In 2002 the FDA requested that Pfizer add a black box warning to Bextra labeling to inform consumers about skin related Bextra injury risks. A black box warning is the strongest warning the FDA can order short of a Bextra recall. Pfizer refused to comply with this government request for over two years. In effect, the pharmaceutical giant intentionally chose not to inform patients about serious and deadly Bextra injury risks.

In addition to skin and cardiovascular Bextra injury risks, Bextra use also increases a person's risk of suffering a gastrointestinal Bextra injury. Anaphylactic shock is another notable Bextra injury that can be caused by this defective drug.

People who have suffered damages as a result of this dangerous and defective drug may be eligible to receive compensation for their Bextra injury losses through a civil lawsuit. Bextra injury victims may be eligible to receive compensation for related medical expenses, loss of income, psychological suffering, and more.

If you or a loved one has been injured or killed as a result of Bextra injury, please contact a Bextra Recall Lawyer .

More Bextra Resources

Bextra Consumer Information - Patient FAQ on Bextra, including side effects, warnings and drug information from the FDA.